Exabis Library
Welcome to the e-CCO Library!
P609: Handsewn anastomosis after ileo-colic resection for Crohn’s disease: a lost art?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P609: Impact of accessibility of medical care and socioeconomic class on outcomes of IBD – a nationwide population study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P609: Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P609: Significant variations in practice in managing mild-Crohn’s disease: results from the 2021 Y-ECCO-ClinCom survey
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P609: Uncertain usefulness of infliximab trough levels for therapeutic decision-making in inflammatory bowel disease patients on infliximab maintenance therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P610 Optimising biological therapy in inflammatory bowel disease patients: the role of a virtual biological clinic
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P610: Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P610: Fear of COVID-19 among persons with Inflammatory Bowel Disease according to employment status, educational background and residential setting, as compared to persons with other gastrointestinal conditions
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P610: Penetration, short- and long-term efficacy of anti-TNF-α therapy for ulcerative colitis between 2010–2016 in Hungary
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P610: Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P610: Risk of active Hepatitis B and C infections in the Phases 2 and 3 clinical trial programmes for ustekinumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P610: Safety of COVID-19 vaccine in patients with Inflammatory Bowel Disease: preliminary data of a national study (ESCAPE-IBD)
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P611 Provision of care for pregnant women with IBD in the UK - the current landscape
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P611: A real-world assessment of golimumab effect on quality of life, healthcare resource utilisation and work productivity in patients with ulcerative colitis in Greece: interim results from the GO-LIFE study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P611: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN'S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P611: Incidence, clinical presentation, and severity of SARS-CoV-2 infection in IBD patients in the second and the third wave of infection
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P611: Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P611: Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P611: Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P612 Dietary practices and beliefs of British South Asians with inflammatory bowel disease: A prospective UK study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM